spacer
The Healthcare Sales & Marketing Network celebrates 26 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  DAVANAT 

 HSMN NewsFeed - 2 Jun 2011
Galectin Therapeutics Announces the Appointment of Kevin Freeman and John Mauldin to the Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 9 Mar 2011
Pro-Pharmaceuticals Names Peter G. Traber, M.D., Former GlaxoSmithKline Chief Medical Officer & President Emeritus of Baylor College of Medicine, President & Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 29 Mar 2010
Pro-Pharmaceuticals Licenses to PROCAPS S.A. Exclusive Marketing and Distribution Rights to Commercialize DAVANAT(R) to Treat Cancer in Colombia, South America
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 17 Jul 2009
Pro-Pharmaceuticals Prevails in Trade Secret Lawsuit
Biopharmaceuticals Oncology Litigation
 HSMN NewsFeed - 29 Jan 2009
FDA Provides Clear Path to NDA Submission for Pro-Pharmaceuticals’ DAVANAT(R)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 24 Mar 2008
Pro-Pharmaceuticals Announces DAVANAT(R) Regimen Approved to Treat Breast Cancer Patient
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 3 Mar 2008
Pro-Pharmaceuticals DAVANAT(R) Extends Median Survival 6.7 Months for End-Stage Colorectal Cancer Patients After All Other Treatments Failed
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Feb 2008
New Data Shows DAVANAT(R) Extends Survival of End-Stage Colorectal Cancer Patients More Than 6 Months
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Oct 2007
Pro-Pharmaceuticals Names Anthony Squeglia Chief Financial Officer; Steven Schubert Vice President Finance
Biopharmaceuticals Personnel
 HSMN NewsFeed - 24 Sep 2007
Pro-Pharmaceuticals Names Theodore Zucconi, Ph.D., President; Nominated to the Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 16 Aug 2007
Pro-Pharmaceuticals Announces ''Compassionate Use'' IND for DAVANAT(R) to Treat Biliary Cancer Patient
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 9 Jul 2007
Pro-Pharmaceuticals Updates Progress of Clinical Trials & DAVANAT(R) 505 (b)(2) Filings
Biopharmaceuticals Oncology Drug Delivery
 HSMN NewsFeed - 17 Apr 2007
Pro-Pharmaceuticals Issues Corporate Update
Biopharmaceuticals
 HSMN NewsFeed - 12 Apr 2007
Pro-Pharmaceuticals Plans to Submit a New Drug Application for DAVANAT(R), as a Functional Excipient, with 5-FU to Treat Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Apr 2007
Pro-Pharmaceuticals Receives Letter from the FDA for New Drug Application for DAVANAT(R)/ 5-FU
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 4 Apr 2007
Pro-Pharmaceuticals Announces Tampa General Hospital Dosing Patients with DAVANAT(R)/5-FU in Phase II, First Line, Advanced Biliary Cancer Clinical Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Feb 2007
Pro-Pharmaceuticals Submits Orphan Drug Status Application to European Medicines Agency Co-administration of DAVANAT(R) with 5-FU to Treat Cholangiocarcinoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 23 Feb 2007
Pro-Pharmaceuticals Meeting Scheduled with the FDA
Biopharmaceuticals Oncology
 HSMN NewsFeed - 7 Feb 2007
Pro-Pharmaceuticals' Begins Process of New Drug Application Submission with the FDA for Co-administration of DAVANAT(R) with 5-FU in Cancer Patients
Biopharmaceuticals Oncology
Return to NewsFeed  

 Additional items found! 19

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 19 additional stories matching:
DAVANAT
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.